{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:07:17Z","timestamp":1785366437189,"version":"3.55.0"},"reference-count":26,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy represents a promising frontier in oncology, but its application to high-grade gliomas (HGG) is challenged by the blood-brain barrier, limited efficacy, and significant toxicities associated with systemic administration. Locoregional delivery has the potential to address these shortcomings. This systematic review evaluates the safety and efficacy of locoregional vs systemic CAR-T cell delivery for HGG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, a total of 112 studies were identified from three separate databases between 2015 and 2024. Of these, 19 articles were assessed for eligibility, resulting in 16 articles meeting the inclusion criteria with 194 treated patients across 14 clinical trials. A comparative meta-analysis was performed to compare the safety and efficacy outcomes of locoregional administration (eg, intracerebroventricular, intratumoral) with systemic (intravenous) delivery. Severe (grade \u22653) adverse event rates and therapeutic responses were pooled to calculate crude incidence, rate ratios, and relative risks (RRs) with 95% CIs. Both fixed-effect and random-effects models were used to evaluate incidence rate ratios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Locoregional delivery was associated with a markedly improved safety profile, demonstrating an over 60% reduction in the incidence of grade \u22653 adverse events compared with systemic infusion (RR=0.39; 95%\u2009CI 0.30 to 0.52; p&lt;0.001). Furthermore, locoregional strategies demonstrated encouraging signals of antitumor activity, including rates of disease responses not widely observed with systemic approaches (RR=3.79; 95%\u2009CI 1.23 to 11.70; p&lt;0.05). Locoregional delivery also enables the analysis of cerebrospinal fluid to monitor T-cell trafficking and emerging biomarkers of immune activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intracranial delivery of CAR-T cells helps overcome key barriers that limit the efficacy and safety of systemic therapy in brain tumors. These findings support a paradigm shift that integrates locoregional delivery techniques as a pivotal component in the design of future CAR-T cell trials, offering a safer and potentially more effective therapeutic approach with greater opportunities for longitudinal sampling for patients with HGG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014450","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:19Z","timestamp":1774626619000},"page":"e014450","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02208362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185038","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02208362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03500991","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04099797","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04099797","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-9435","authenticated-orcid":false,"given":"Christian K","family":"Ramsoomair","sequence":"first","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Medical Scientist Training Program, University of Miami Leonard M Miller School of Medicine, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Daftari","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Benchouia","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Estevez-Ordonez","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4252-7456","authenticated-orcid":false,"given":"Anurag","family":"Aka","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratko","family":"Himic","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Aramburu-Berckemeyer","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kreatsoulas","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidya","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S","family":"Chandar","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Ivan","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J","family":"Komotar","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-1274","authenticated-orcid":false,"given":"Ashish","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Miami Department of Neurological Surgery, Miami, Florida, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026032708501118000_14.3.e014450.1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026032708501118000_14.3.e014450.2","doi-asserted-by":"crossref","DOI":"10.3390\/cells13090726","article-title":"A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives","volume":"13","author":"Montoya","year":"2024","journal-title":"Cells"},{"key":"2026032708501118000_14.3.e014450.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026032708501118000_14.3.e014450.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2"},{"key":"2026032708501118000_14.3.e014450.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0821-8"},{"key":"2026032708501118000_14.3.e014450.6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"2026032708501118000_14.3.e014450.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497"},{"key":"2026032708501118000_14.3.e014450.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026032708501118000_14.3.e014450.9","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000260"},{"key":"2026032708501118000_14.3.e014450.10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: A phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"2026032708501118000_14.3.e014450.11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026032708501118000_14.3.e014450.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1"},{"key":"2026032708501118000_14.3.e014450.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03451-3"},{"key":"2026032708501118000_14.3.e014450.14","first-page":"v108","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026032708501118000_14.3.e014450.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-025-05251-2","article-title":"Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review","volume":"176","author":"Mahdi","year":"2025","journal-title":"J Neurooncol"},{"key":"2026032708501118000_14.3.e014450.16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature New Biol"},{"key":"2026032708501118000_14.3.e014450.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4"},{"key":"2026032708501118000_14.3.e014450.18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","article-title":"Complex neural-immune interactions shape glioma immunotherapy","volume":"58","author":"Song","year":"2025","journal-title":"Immunity"},{"key":"2026032708501118000_14.3.e014450.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8"},{"key":"2026032708501118000_14.3.e014450.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019"},{"key":"2026032708501118000_14.3.e014450.21","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/neuonc\/noaf195","article-title":"Targeting TGF\u03b2 docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma","volume":"27","author":"Wu","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026032708501118000_14.3.e014450.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0428"},{"key":"2026032708501118000_14.3.e014450.23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac024"},{"key":"2026032708501118000_14.3.e014450.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390"},{"key":"2026032708501118000_14.3.e014450.25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0750"},{"key":"2026032708501118000_14.3.e014450.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:21Z","timestamp":1774626621000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014450"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014450","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}